Skip to main
KTTA

KTTA Stock Forecast & Price Target

KTTA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pasithea Therapeutics is a biotechnology company with a promising pipeline focused on the discovery and development of treatments for central nervous system disorders and other diseases. The recent protocol amendment for its Phase 1/1b trial of PAS-004 in NF1 patients allows for a more comprehensive evaluation of the drug's efficacy, potentially de-risking its future development. The company's strategic plans for their lead asset, PAS-004, in both NF1 and oncology markets, as well as the recent RPDD and PRV granted by the FDA, present significant upside value potential for investors, despite being in the early stages of clinical development. Overall, Pasithea Therapeutics has strong potential to become a key player in the biotechnology industry.

Bears say

Pasithea Therapeutics is currently overvalued as the market has not fully accounted for the potential risks associated with their advanced cancer study and the unmet medical need for their PAS-004 drug for Neurofibromatosis Type 1. The company's current market model for PAS-004 is conservative and may not accurately depict the commercial potential of the drug. Furthermore, the company has limited revenue streams, with only one reportable segment, which could make it vulnerable to market volatility.

KTTA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pasithea Therapeutics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pasithea Therapeutics Corp (KTTA) Forecast

Analysts have given KTTA a Strong Buy based on their latest research and market trends.

According to 1 analysts, KTTA has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pasithea Therapeutics Corp (KTTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.